Abstract
G-protein coupled receptors (GPCRs) are the most important class of current pharmacological targets. However, it is now widely acknowledged that their regulation is more complex than previously thought: the evidence that GPCRs can couple to several effector pathways, and the existence of biased agonists able to activate them differentially, has introduced a new level of complexity in GPCR drug research. Considering bias represents a challenge for the research of new GPCR modulators, because it demands a detailed characterization of compound properties for several effector pathways. Still, biased ligands could provide an opportunity to modulate GPCR function in a finer way and to separate therapeutic from side effects.
Nowadays, a variety of agonists for GPCRs have been described, which differ in their ability to promote receptor coupling to different Gprotein families or even subunits, recruit signal transducers such as arrestins, activate a variety of downstream molecular pathways and induce certain phosphorylation signatures or gene expression patterns. In this review, we will cover some of the experimental techniques currently used to understand and characterize biased agonism and discuss their strengths and limitations. Additionally, we will comment on the computational efforts that are being devoted to study ligand-induced bias and on the potential they hold for rationalizing its structural determinants. Finally, we will discuss which of these strategies could be used for the rational design of biased ligands and give some examples of the potential therapeutic value of this class of compounds.
Keywords: GPCR, biased agonism, functional selectivity, drug discovery.
Current Pharmaceutical Design
Title:Novel Insights into Biased Agonism at G Protein-Coupled Receptors and their Potential for Drug Design
Volume: 19 Issue: 28
Author(s): Maria Marti-Solano, Ramon Guixa-Gonzalez, Ferran Sanz, Manuel Pastor and Jana Selent
Affiliation:
Keywords: GPCR, biased agonism, functional selectivity, drug discovery.
Abstract: G-protein coupled receptors (GPCRs) are the most important class of current pharmacological targets. However, it is now widely acknowledged that their regulation is more complex than previously thought: the evidence that GPCRs can couple to several effector pathways, and the existence of biased agonists able to activate them differentially, has introduced a new level of complexity in GPCR drug research. Considering bias represents a challenge for the research of new GPCR modulators, because it demands a detailed characterization of compound properties for several effector pathways. Still, biased ligands could provide an opportunity to modulate GPCR function in a finer way and to separate therapeutic from side effects.
Nowadays, a variety of agonists for GPCRs have been described, which differ in their ability to promote receptor coupling to different Gprotein families or even subunits, recruit signal transducers such as arrestins, activate a variety of downstream molecular pathways and induce certain phosphorylation signatures or gene expression patterns. In this review, we will cover some of the experimental techniques currently used to understand and characterize biased agonism and discuss their strengths and limitations. Additionally, we will comment on the computational efforts that are being devoted to study ligand-induced bias and on the potential they hold for rationalizing its structural determinants. Finally, we will discuss which of these strategies could be used for the rational design of biased ligands and give some examples of the potential therapeutic value of this class of compounds.
Export Options
About this article
Cite this article as:
Marti-Solano Maria, Guixa-Gonzalez Ramon, Sanz Ferran, Pastor Manuel and Selent Jana, Novel Insights into Biased Agonism at G Protein-Coupled Receptors and their Potential for Drug Design, Current Pharmaceutical Design 2013; 19 (28) . https://dx.doi.org/10.2174/1381612811319280014
DOI https://dx.doi.org/10.2174/1381612811319280014 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos
Current Metabolomics Animal Models of Gastric Bleeding Induced by Dual Antiplatelet Therapy Using Aspirin and Clopidogrel - Prophylactic Effect of Antiulcer Drugs
Current Pharmaceutical Design Heart Failure Epidemiology: European Perspective
Current Cardiology Reviews Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology The Relaxin Peptide Family – Structure, Function and Clinical Applications
Protein & Peptide Letters Recent Patents on Wireless Capsule Endoscopy
Recent Patents on Biomedical Engineering (Discontinued) Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Immunosuppression and Post-transplant Hyperglycemia
Current Diabetes Reviews Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology